וזמינותו מבוססי Cytometry זרימה מודדים פוטנציאל ממברנה מיטוכונדריאלי של תאי שריר הלב לאחר היפוקסיה/Reoxygenation

Executive Industry Relevance

Assessing mitochondrial membrane potential (MMP) is critical for evaluating cardioprotective strategies in ischemia-reperfusion injury models. This flow cytometry-based JC-1 assay provides a quantitative, high-throughput readout of mitochondrial depolarization in human cardiac myocytes, enabling mechanistic de-risking of therapeutic candidates targeting reperfusion injury. The method supports target validation by linking MMP changes to mitochondrial permeability transition pore (mPTP) opening, a key event in cardiomyocyte death.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Measures MMP as a functional readout of mitochondrial health and mPTP opening in disease-relevant human cardiac myocytes.
• Operational Value: Enables interrogation of therapeutic hypotheses regarding cytoprotective agents under hypoxia/reoxygenation stress.
• Predictive Value: Supports target confidence by correlating MMP preservation with reduced apoptosis, as demonstrated by Annexin PI ratio.

Screening & Assay Development

• Scientific Value: JC-1’s red/green fluorescence ratio provides a ratiometric, mitochondria-specific readout independent of cell size or granularity.
• Operational Value: Low material requirements and compatibility with standard flow cytometry platforms support assay scalability and reproducibility.
• Screening Readiness: Enables rapid evaluation of compound libraries for effects on MMP in a physiologically relevant human cell model.

Translational & Preclinical Research

• Scientific Value: Uses human cardiac myocytes to enhance translational relevance over rodent models in ischemia-reperfusion studies.
• Operational Value: Standardized hypoxia/reoxygenation protocol allows consistent induction of mitochondrial depolarization for compound testing.
• Predictive Value: Facilitates go/no-go decisions by linking MMP protection to functional outcomes like reduced apoptosis.

Pipeline & Workflow Integration

The assay fits within the early discovery continuum, supporting target validation and lead identification by providing mechanistic insights into mitochondrial dysfunction in cardiovascular disease models.

• Discovery Biology: Enables hypothesis testing of MMP as a biomarker of mPTP activation and reperfusion injury severity.
• Screening: Delivers quantitative, normalized fluorescence ratio data suitable for hit selection and dose-response profiling.
• Analytics: Generates red/green intensity ratio metrics that allow statistical comparison across treatment groups.
• Translational Research: Uses human-derived cells to improve predictive confidence for preclinical advancement.
• Enterprise Reuse: Protocol can be adapted across cardiotoxicity and cardioprotection screening campaigns.

Operational & Enterprise Impact

• Scientific Value: Provides mechanistic insight into mitochondrial depolarization as a convergent point of reperfusion injury pathways.
• Operational Value: Minimizes variability by normalizing MMP readout to mitochondrial content via ratiometric JC-1 detection.
• Strategic Value: Improves capital efficiency by enabling early identification of compounds that preserve MMP and reduce apoptotic commitment.
• Portfolio Impact: Supports risk-adjusted prioritization of candidates demonstrating MMP stabilization in human cardiac myocytes.

Implementation Considerations

• Requires expertise in primary human cardiac myocyte culture and hypoxia/reoxygenation modeling.
• Dependent on flow cytometry with FITC and PE detection channels and logarithmic fluorescence scaling.
• Necessitates strict temperature control during JC-1 staining to preserve mitochondrial membrane potential integrity.
• Requires standardization of hypoxia duration and reoxygenation timing across experimental groups.
• Limited to adherent cell types amenable to trypsinization and washing without loss of viability.

Biopharma FAQs